188 filings
Page 3 of 10
8-K
yma15r9t2 kj
12 Sep 17
Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress
12:00am
8-K
h6rwgh
5 Sep 17
Departure of Directors or Certain Officers
12:00am
S-8
wxoygagpciqi szsj3
30 Aug 17
Registration of securities for employees
12:00am
EFFECT
3z7 p14jx2pe
28 Aug 17
Notice of effectiveness
12:00am
UPLOAD
zyl68tasdcf43zvfp
24 Aug 17
Letter from SEC
12:00am
CORRESP
280335
24 Aug 17
Correspondence with SEC
12:00am
8-K
rraqzyd 2s8at9r
2 Aug 17
Departure of Directors or Certain Officers
12:00am
CT ORDER
4y63ur
23 Jun 17
Confidential treatment order
12:00am
8-K
2a8 le5dtb5p5qxj
16 Jun 17
Argos Therapeutics Announces $6,000,000 Secured Convertible Note Financing
12:00am
8-K
u7a8m
4 May 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
10-K/A
rv7 uioh0s6
1 May 17
Annual report (amended)
12:00am
CT ORDER
wh2cwvzvcvd 1uxla
27 Apr 17
Confidential treatment order
12:00am
8-K
3fgg1ozynq3nc7bvv
18 Apr 17
Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial
12:00am
8-K
7b5z9nwq
14 Apr 17
Other Events
12:00am
8-K
m53hlx67vzco
4 Apr 17
Departure of Directors or Certain Officers
12:00am